SagentMD

Reprocessed "used/soiled" Single Use medical Devices (SUD's) that the FDA has determined are built robust enough to be disassembled-cleaned-reassembled back to OEM specifications for reuse. High value Cardiovascular, Orthopedic & Laparoscopic reprocessed devices save hospitals & outpatient surgery centers $25-$2,500 per device. This 50% savings in supply cost is coupled with the environmental benefit of reducing expensive regulated waste by the ton. This $4.0B market is in it's infancy only being 20% penetrated and is expected to double within the next few years. J&J & Stryker recently acquired the two market leading pioneers for 5 X revenue. Healthcare providers seek a competitive alternative to this lock-step duopoly. This business runs a 60% EBITDA and Sagent is projected to have $50M/yr in revenue within 5 years.